ACW 3.70% 2.8¢ actinogen medical limited

Innovative-intelligence

  1. 12,499 Posts.
    lightbulb Created with Sketch. 1855
    Apologies if this article have been previously posted:

    Alzheimer’s treatment could be worth $10bn annually
    Paul Brescia • Jul 17, 2020

    An Australian company working on a novel drug for Alzheimer’s is making progress in a field which has seen almost 20 years of stalled progress.

    ASX-listed Actinogen is taking a different approach to its contemporaries: targeting and lowering raised levels of cortisol in the brain which have been linked to cognitive decline.

    Once thought of as a benign consequence of a number of diseases, researchers now recognise raised cortisol as a condition that needs management.
    More importantly, Actinogen’s last series of trials, which gave higher doses of its novel drug to a non-Alzheimer’s affected cohort of older patients, who were cognitively normal but some may have had normal, age-related cognitive decline, demonstrated a cognitive improvement when being dosed at 20mg a day.

    This was proven through standard psychometric test batteries, including short-term and functional memory tests.

    With 500,000 Australians suffering from Alzheimer’s, one of the leading causes of death in Australia, any breakthrough in treatment options could dramatically improve the lives of millions, both those directly affected, and their family or caretakers.

    Dr. Bill Ketelbey, CEO, Actinogen, explained to Innovation Intelligence, “We have done some conservative modelling on our drug. If we can demonstrate that we provide a cognitive benefit to an early Alzheimer’s patient, we have a drug that could conservatively generate over US$10bn in annual revenue.

    “That is not even looking more broadly at opportunities beyond Alzheimer’s, or the broader population suffering cognitive decline.”
    That would make it the second most profitable pharmaceutical drug ever developed.
    If the drug could slow down progression of the disease, and not just treat later-stage patients, “We can not even imagine how big an asset that we would have,” contends Ketelbey.

    “If we can demonstrate our hypothesis is correct, it could open a whole new area of scientific and medical research. We would be the pioneers into a substantial area of medical research and central-nervous system research going forward.”

    https://www.innovation-intelligence.com/alzheimers-treatment-could-be-worth-10bn-annually
 
watchlist Created with Sketch. Add ACW (ASX) to my watchlist
(20min delay)
Last
2.8¢
Change
0.001(3.70%)
Mkt cap ! $31.25M
Open High Low Value Volume
2.8¢ 2.8¢ 2.8¢ $23.45K 834.2K

Buyers (Bids)

No. Vol. Price($)
2 187000 2.8¢
 

Sellers (Offers)

Price($) Vol. No.
2.9¢ 567796 1
View Market Depth
Last trade - 15.56pm 18/09/2020 (20 minute delay) ?
(live)
Last
2.9¢
  Change
0.001 ( 3.57 %)
Open High Low Volume
2.8¢ 2.9¢ 2.8¢ 635990
Last updated 15.19pm 18/09/2020 (live) ?
ACW (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.